m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT03065
 [1]
Histone modification H3K27ac KAT3A WTAP Direct Enhancement m6A modification DIAPH1-AS1 DIAPH1-AS1 WTAP Methylation : m6A sites
m6A Modification:
m6A Regulator Wilms tumor 1-associating protein (WTAP) WRITER
 Regulator Info 
m6A Target DIAPH1 antisense RNA 1 (DIAPH1-AS1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Histone modification (HistMod)
Epigenetic Regulator CREB-binding protein (CREBBP) WRITER View Details
Regulated Target Histone H3 lysine 27 acetylation (H3K27ac) View Details
Downstream Gene WTAP View Details
Crosstalk Relationship Histone modification  →  m6A Enhancement
Crosstalk Mechanism histone modification directly impacts m6A modification through modulating the level of m6A regulator
Crosstalk Summary WTAP upregulated in NPC was fine-tuned by CREBBP-mediated Histone H3 lysine 27 acetylation (H3K27ac). WTAP-mediated m6A modification of lncRNA DIAPH1 antisense RNA 1 (DIAPH1-AS1) enhances its stability to facilitate nasopharyngeal carcinoma growth and metastasis
Responsed Disease Nasopharyngeal carcinoma ICD-11: 2B6B
 Disease Info 
In-vitro Model
NP69SV40T
 N.A. Homo sapiens CVCL_F755
N2Tert (The human immortalized nasopharyngeal epithelial cell lines)
In-vivo Model About in vivo tumorigenesis model, 1 × 106 indicated SUNE-1 cells were subcutaneously injected into the flanks of nude mice. The tumor volumes were measured every 4 days. On day 32 after injection, the mice were sacrificed and the subcutaneous tumors were excised and weighed. For the inguinal lymph node metastasis model, 2 × 105 indicated SUNE-1 cells were injected into the footpads of nude mice.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
CREB-binding protein (CREBBP) 8 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name PRI-724 Phase 1/2 [2]
MOA Modulator
External Link
CID: 71509318
TTD: D0Q0ZY
DrugBank: DB15034
 Compound Name C 82 Phase 1/2 [3]
Synonyms
N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 75202656
TTD: D0DA5M
 Compound Name CCS1477 Phase 1/2 [4]
Synonyms
CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 134457551
TTD: DIY4C2
 Compound Name FT-7051 Phase 1 [5]
MOA Inhibitor
External Link
TTD: DT8IL6
 Compound Name Pyrrolo-pyrrolone derivative 6 Patented [6]
Synonyms
PMID26924192-Compound-39
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 91 nM
External Link
CID: 122553484
TTD: D0O9WQ
 Compound Name ischemin Investigative [7]
Synonyms
MS120
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 5000 nM
External Link
CID: 135566302
TTD: D00DXI
 Compound Name SGC-CBP30 Investigative [8]
Synonyms
1613695-14-9; (s)-4-(1-(2-(3-chloro-4-methoxyphenethyl)-5-(3,5-dimethylisoxazol-4-yl)-1h-benzo[d]imidazol-1-yl)propan-2-yl)morpholine; 2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-1,3-benzodiazole; 2-[2-(3-Chloro-4-Methoxyphenyl)ethyl]-5-(3,5-Dimethyl-1,2-Oxazol-4-Yl)-1-[(2s)-2-(Morpholin-4-Yl)propyl]-1h-Benzimidazole; 2LO; C28H33ClN4O3; GTPL7529; SCHEMBL17512896; CHEMBL3622373; AOB4800; MolPort-035-395-859; BDBM188519; EX-A2159; ZINC96170456; s7256
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 30 nM
External Link
CID: 72201027
TTD: D03XXT
 Compound Name I-CBP112 Investigative [9]
Synonyms
1640282-31-0; I-CBP 112; CHEMBL3774655; 1-[7-(3,4-Dimethoxyphenyl)-9-[[(3S)-1-methylpiperidin-3-yl]methoxy]-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; 1-[7-(3,4-dimethoxyphenyl)-9-{[(3S)-1-methylpiperidin-3-yl]methoxy}-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; GTPL8236; SCHEMBL17620385; MolPort-035-765-871; EX-A2474; ZINC96024493; BDBM50151663; AKOS024458402; CS-6146; NCGC00350526-04; HY-19541; I-CBP112, &gt
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 440 nM
External Link
CID: 90488984
TTD: D0J3JI
2B6B: Nasopharyngeal carcinoma 20 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Lotilaner Approved [10]
External Link
TTD: DV87CQ
 Compound Name Toripalimab Approved in China [11]
External Link
TTD: D92OCI
 Compound Name Tabelecleucel Phase 2 [12]
Synonyms
Tab-cel
    Click to Show/Hide
External Link
TTD: DY4Q6M
 Compound Name A167 Phase 3 [13]
Synonyms
KL-A167
    Click to Show/Hide
External Link
TTD: DI89WD
 Compound Name MLN4924 Phase 1 [14]
Synonyms
Pevonedistat; 905579-51-3; MLN-4924; MLN 4924; UNII-S3AZD8D215; S3AZD8D215; Sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl ester; ((1S,2S,4R)-4-(4-(((S)-2,3-dihydro-1H-inden-1-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate; C21H25N5O4S; [(1s,2s,4r)-4-{4-[(1s)-2,3-Dihydro-1h-Inden-1-Ylamino]-7h-Pyrrolo[2,3-D]pyrimidin-7-Yl}-2-Hydroxycyclopentyl]methyl Sulfamate; Pevonedistat [USAN:INN]; 3gzn
    Click to Show/Hide
External Link
CID: 16720766
TTD: D0ZD2M
DrugBank: DB11759
 Compound Name TT10 Phase 3 [15]
Synonyms
EBVST; GVYPHJQPOHDZEI-UHFFFAOYSA-N; TT-10; 2230640-94-3
    Click to Show/Hide
External Link
CID: 134827875
TTD: D0NS3O
 Compound Name DE-766 Phase 3 [16]
External Link
TTD: D0FJ1W
 Compound Name Avastin+/-Tarceva Phase 3 [17]
Synonyms
Juglone; 481-39-0; 5-Hydroxy-1,4-naphthoquinone; 5-Hydroxy-1,4-naphthalenedione; Regianin; Juglon; Nucin; 5-Hydroxynaphthalene-1,4-dione; Walnut extract; 5-Hydroxynaphthoquinone; Akhnot; Yuglon; 8-Hydroxy-1,4-naphthoquinone; CI Natural Brown 7; 1,4-NAPHTHALENEDIONE, 5-HYDROXY-; 5-Hydroxy-p-naphthoquinone; 1,4-Naphthoquinone, 5-hydroxy-; CI 75500; Juglane; Jugnlon; Iuglon; Caswell No 515AA; 1,4-Naphthoquinone, 8-hydroxy-; 5-Hydroxy-1,4-naphthosemiquinone; 5-Hydroxy-1,4-naftochinon; UNII-W6Q80SK9L6; NSC 622948; NSC 153189; CCRIS
    Click to Show/Hide
External Link
CID: 3806
TTD: D0C0NH
 Compound Name MK-2206 Phase 2 [18]
Synonyms
1032349-93-1; UNII-51HZG6MP1K; MK 2206; 51HZG6MP1K; CHEMBL1079175; CHEBI:67271; NCGC00186465-01; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one; DSSTox_RID_83143; DSSTox_CID_28874; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; DSSTox_GSID_48948; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; 1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-;
    Click to Show/Hide
External Link
CID: 24964624
TTD: D0W3RW
 Compound Name R-roscovitine Phase 2 [19]
Synonyms
Seliciclib; roscovitine; 186692-46-6; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; UNII-0ES1C2KQ94; Roscovitine (Seliciclib,CYC202); NSC 701554; AL-39256; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; NSC701554; NSC-701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; Rosco; M02443; BMK1-E12; CYC202, Seliciclib, R-roscovitine, Roscovitine; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-(R)-1-butanol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine
    Click to Show/Hide
External Link
CID: 160355
TTD: D05ADP
DrugBank: DB06195
 Compound Name Epstein-barr virus-specific immunotherapy Phase 2 [20]
Synonyms
Epstein-barr virus-specific immunotherapy (nasopharyngeal carcinoma)
    Click to Show/Hide
External Link
TTD: D03XEY
 Compound Name LMP1-CAR-T cells Phase 1/2 [21]
External Link
TTD: D0RJ2V
 Compound Name APG-1387 Phase 1 [22]
Synonyms
AKLBERUGKZNEJY-RTEPGWBGSA-N; SCHEMBL15490706
    Click to Show/Hide
External Link
CID: 73336238
TTD: D0NP8P
 Compound Name GSK618334 Phase 1 [23]
Synonyms
Fingolimod hydrochloride; 162359-56-0; FTY720; Fingolimod HCl; Gilenya; Gilenia; Fty-720; Fty 720; Fingolimod (FTY720) HCl; Fingolimod (hydrochloride); 2-Amino-2-(4-octylphenethyl)propane-1,3-diol hydrochloride; 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride; UNII-G926EC510T; Fingolimod hydrochloride [USAN]; CHEBI:63112; G926EC510T; 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride; AK-33554; 2-AMINO-2-[2-(4-OCTYL-PHENYL)-ETHYL]-PROPANE-1,3-DIOL HCL; Fingolimod-d4 Hydrochloride
    Click to Show/Hide
External Link
CID: 107969
TTD: D0HI1K
 Compound Name PD173074 Investigative [24]
External Link
CID: 1401
TTD: D0VF6E
 Compound Name Ad5f35-LMPd1-2-transduced autologous dendritic cells Investigative [25]
Synonyms
AddLMP1-I-LMP2; LMP1/LMP2 cytotoxic T-lymphocytes vaccine (nasopharyngeal cancer), Baylor College of Medicine; Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer); Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer),NCI
    Click to Show/Hide
External Link
TTD: D0Q8PF
 Compound Name THZ1 Investigative [26]
Synonyms
HY-80013
    Click to Show/Hide
External Link
CID: 73602827
TTD: D0LO5B
 Compound Name SAIT301 Investigative [16]
External Link
TTD: D07QNH
 Compound Name HITOPK-032 Investigative [27]
Synonyms
HI-TOPK-32; HI-TOPK-032; C20H11N5OS; N-(12-cyanoindolizino[2,3-b]quinoxalin-2-yl)thiophene-2-carboxamide; 799819-78-6; N-(12-cyano-2-indolizino[2,3-b]quinoxalinyl)-2-thiophenecarboxamide; AC1LYXW6; HI-TOPC-032; SCHEMBL15270774; DTXSID00365681; AOB1064; SYN5181; MolPort-002-572-638; ACN-S001950; ZINC2320807; STK548195; AKOS005476059; CS-6900; MCULE-6063579279; ACN-001741; AS-16541; HY-101550; B5640; J3.626.778J
    Click to Show/Hide
External Link
CID: 1936439
TTD: D06DPJ
 Compound Name Ro5203280 Investigative [28]
Synonyms
Ro3280; Ro 3280; PharmaGSID_48511; 4-((9-Cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide; DJNZZLZKAXGMMC-UHFFFAOYSA-N; 79C; DSSTox_RID_82762; DSSTox_CID_28485; DSSTox_GSID_48511; SCHEMBL1559146; GTPL9403; DTXSID4048511; AOB5394
    Click to Show/Hide
External Link
CID: 25015677
TTD: D05WDM
References
Ref 1 WTAP-mediated m(6)A modification of lncRNA DIAPH1-AS1 enhances its stability to facilitate nasopharyngeal carcinoma growth and metastasis. Cell Death Differ. 2022 Jun;29(6):1137-1151. doi: 10.1038/s41418-021-00905-w. Epub 2022 Jan 8.
Ref 2 Inhibition of Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis. Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14309-14. doi: 10.1073/pnas.1001520107. Epub 2010 Jul 21.
Ref 3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 4 Targeting the p300/CBP Axis in Lethal Prostate Cancer. Cancer Discov. 2021 May;11(5):1118-1137. doi: 10.1158/2159-8290.CD-20-0751. Epub 2021 Jan 11.
Ref 5 Clinical pipeline report, company report or official report of FORMA Therapeutics.
Ref 6 BET inhibitors in cancer therapeutics: a patent review. Expert Opin Ther Pat. 2016;26(4):505-22. doi: 10.1517/13543776.2016.1159299. Epub 2016 Mar 15.
Ref 7 A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes. Chem Biol. 2011 Apr 22;18(4):531-41. doi: 10.1016/j.chembiol.2010.12.021.
Ref 8 Bromodomains and their pharmacological inhibitors. ChemMedChem. 2014 Mar;9(3):438-64. doi: 10.1002/cmdc.201300434. Epub 2014 Feb 4.
Ref 9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2734).
Ref 10 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 217603
Ref 11 Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol. 2022 Jan 12;12:730666.
Ref 12 ClinicalTrials.gov (NCT00953420) Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes (CADEN). U.S. National Institutes of Health.
Ref 13 ClinicalTrials.gov (NCT05294172) KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Clinical Trial. U.S.National Institutes of Health.
Ref 14 Promoting tumorigenesis in nasopharyngeal carcinoma, NEDD8 serves as a potential theranostic target.Cell Death Dis. 2017 Jun 1;8(6):e2834.
Ref 15 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 16 Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
Ref 17 Overexpression of PIN1 Enhances Cancer Growth and Aggressiveness with Cyclin D1 Induction in EBV-Associated Nasopharyngeal Carcinoma.PLoS One. 2016 Jun 3;11(6):e0156833.
Ref 18 UBE2T promotes nasopharyngeal carcinoma cell proliferation, invasion, and metastasis by activating the AKT/GSK3/-catenin pathway.Oncotarget. 2016 Mar 22;7(12):15161-72.
Ref 19 Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma.Clin Cancer Res. 2009 Jun 1;15(11):3716-24.
Ref 20 ClinicalTrials.gov (NCT00834093) A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma. U.S. National Institutes of Health.
Ref 21 ClinicalTrials.gov (NCT02980315) A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application
Ref 22 XIAP Limits Autophagic Degradation of Sox2 and Is A Therapeutic Target in Nasopharyngeal Carcinoma Stem Cells.Theranostics. 2018 Feb 5;8(6):1494-1510.
Ref 23 Sphingosine kinase 1 is a potential therapeutic target for nasopharyngeal carcinoma. Oncotarget. 2016 Dec 6;7(49):80586-80598. doi: 10.18632/oncotarget.13014.
Ref 24 Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma.Cancer Biol Ther. 2014;15(12):1613-21.
Ref 25 CA patent application no. 876139, Nanotherapeutics for drug targeting.
Ref 26 Super-Enhancers Promote Transcriptional Dysregulation in Nasopharyngeal Carcinoma.Cancer Res. 2017 Dec 1;77(23):6614-6626.
Ref 27 PDZ binding kinase (PBK) is a theranostic target for nasopharyngeal carcinoma: driving tumor growth via ROS signaling and correlating with patient survival.Oncotarget. 2016 May 3;7(18):26604-16.
Ref 28 Polo-like kinase inhibitor Ro5203280 has potent antitumor activity in nasopharyngeal carcinoma.Mol Cancer Ther. 2013 Aug;12(8):1393-401.